Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Katsuhiro Shinjo"'
Autor:
Katsuhiro Shinjo, Shawna R. Calhoun, Kaname Ueda, Hiroyuki Enomoto, Amir Goren, Nao Sasaki, Takeshi Muneta
Publikováno v:
Clinical Interventions in Aging
Kaname Ueda,1 Nao Sasaki,2 Amir Goren,3 Shawna R Calhoun,4 Katsuhiro Shinjo,5 Hiroyuki Enomoto,5 Takeshi Muneta6 1Health Outcomes/Health Technology Assessment/Real World Evidence, Eli Lilly Japan, Kobe, Japan; 2Bio-Medicines, Medicines Development Un
Publikováno v:
Pharmacology. 82:245-249
GPR35 is a Gi/o- and G16-coupled receptor abundantly expressed in gastrointestinal tissues and immune cells. Kynurenic acid (a tryptophan metabolite and ionotropic glutamate receptor antagonist) and zaprinast (a phosphodies- terase inhibitor) are GPR
Publikováno v:
Journal of Neuroscience Methods. 165:49-54
Sensory information is conveyed to the central nervous system by primary afferent neurons within dorsal root ganglia (DRG), which synapse onto neurons of the dorsal horn of the spinal cord. This synaptic connection is central to the processing of bot
Autor:
Katsuhiro Shinjo, John B. Furness, Ian M. Coupar, Billie Hunne, Helen Irving, Shir Lin Koh, Daniel P. Poole, Bo Xu
Publikováno v:
Cell and Tissue Research. 325:413-422
5-Hydroxytryptamine (5-HT) is an endogenous stimulant of intestinal propulsive reflexes. It exerts its effects partly through 5-HT4 receptors; 5-HT4 receptor agonists that are stimulants of intestinal transit are in clinical use. Both pharmacological
Autor:
Hyung Suk Kim, Marsha L. Roach, John D. McNeish, John E. Burkhardt, Katsuhiro Shinjo, Kana Taniguchi, Thomas M. Coffman, Toshihisa Ishikawa, Jeffrey L. Stock, Patrick J. Flannery, Laurent P. Audoly
Publikováno v:
Journal of Clinical Investigation. 107:325-331
The lipid mediator prostaglandin E2 (PGE2) has diverse biological activity in a variety of tissues. Four different receptor subtypes (EP1–4) mediate these wide-ranging effects. The EP-receptor subtypes differ in tissue distribution, ligand-binding
Autor:
Kana Taniguchi, Atsushi Nagahisa, Katsuhiro Shinjo, Kaoru Shimada, Mayumi Mizutani, Frank S. Menniti, Toshihisa Ishikawa
Publikováno v:
British Journal of Pharmacology. 122:809-812
1. The analgesic activity of CP-101,606, an NR2B subunit-selective N-methyl-D-aspartate (NMDA) receptor antagonist, was examined in carrageenan-induced hyperalgesia, capsaicin- and 4beta-phorbol-12-myristate-13-acetate (PMA)-induced nociceptive tests
Autor:
Yoshinobu Ueno, Yoshiko Goda, Atsushi Nagahisa, Atsushi Nakamura, Katsuhiro Shinjo, Takaaki Nakamura
Publikováno v:
European Journal of Pharmacology. 322:83-89
Dimaprit, a selective histamine H2 receptor agonist, was examined in experimental models of endotoxin shock and hepatitis in mice. Injection of lipopolysaccharide (8 mg/kg i.v.) into Balb/c mice resulted in an elevation of plasma tumor necrosis facto
Autor:
Aki Saigo, Rie Nakashima, Takeru Nose, Ryo Hatano, Tsugumi Fujita, Tetsujo Sujaku, Katsuhiro Shinjo, Atsushi Nagahisa, Yasuyuki Shimohigashi
Publikováno v:
Journal of Biological Chemistry. 271:23642-23645
Nociceptin or orphanin FQ is a novel neuropeptide that activates an opioid-like G protein-coupled receptor ORL1. This heptadecapeptide FGGFTGARKSARKLANQ resembles kappa-opioid peptide dynorphin A but exhibits an opposite effect to make animals hyperr
Autor:
Masatoshi Hori, Akira Imasato, Hideaki Shimada, Hiroshi Ozaki, Yoshihito Morizane, Takashi Ochi, Katsuhiro Shinjo
Publikováno v:
Liver international : official journal of the International Association for the Study of the Liver. 30(1)
Background: Myofibroblast-like cells derived from transdifferentiated hepatic stellate cells (HSC) play a central role in scar formation that leads to liver fibrosis. The molecular mechanisms underlying this process are not fully understood. Aim: Our
Autor:
Naoto Kato, Aisuke Nii, Hiroyuki Eda, Takashi Ochi, Midori Kojima, Daisuke Hirano, Katsuhiro Shinjo
Publikováno v:
Hepatology research : the official journal of the Japan Society of Hepatology. 39(4)
AIM The aim of this study was to investigate the hepatoprotective activity of a selective cannabinoid receptor 1 (CB1) antagonist, SR141716A, in a Concanavalin A (Con A)-induced mouse liver injury model and to determine whether SR141716A has an effec